United States Hemoglobin A1c Testing Devices for Diabetes Market was valued at USD 0.7 Billion in 2022 and is projected to reach USD 1.3 Billion by 2030, growing at a CAGR of 8.7% from 2024 to 2030.
The Hemoglobin A1c Testing Devices for Diabetes Market in the United States has experienced significant growth, driven by the escalating prevalence of diabetes and the increasing emphasis on effective disease management. In 2023, the U.S. market generated a revenue of USD 765.6 million and is projected to reach USD 1,126.7 million by 2030, reflecting a compound annual growth rate (CAGR) of 5.7% from 2024 to 2030.
Two primary categories of HbA1c testing devices dominate the market:
Point-of-Care (POC) Testing Devices: These devices accounted for approximately 76.53% of the market share in 2023. Their rapid results and user-friendly interface make them indispensable in various healthcare settings, including clinics, pharmacies, and even homes. The convenience they offer aligns with the growing trend towards decentralized healthcare, allowing for immediate clinical decision-making and enhanced patient engagement.
Laboratory-based Testing Devices: Valued for their high accuracy and reliability, these devices are predominantly utilized in hospital laboratories and diagnostic centers. Operated by trained professionals, they ensure precise measurements of glycated hemoglobin levels, which are crucial for informed diabetes management decisions.
The industry's landscape is characterized by continuous innovation and strategic collaborations. For instance, in February 2024, HemoCue partnered with Novo Nordisk to enhance point-of-care diagnostic testing for children with type 1 diabetes in low- and middle-income countries. This collaboration aims to deploy HemoCue HbA1c 501 Systems across 30 countries, improving diabetes management and reaching 100,000 children by 2030. Such initiatives underscore the commitment to expanding access to essential diagnostic tools globally.
Technological advancements have also played a pivotal role in shaping the market. The integration of microfluidic immunofluorescence tests, such as LumiraDx's HbA1c test, exemplifies this trend. Achieving CE Marking in May 2022, this test delivers rapid results in under seven minutes, facilitating swift screening and monitoring of diabetic patients. Additionally, the development of compact, automated HPLC analyzers like Trivitron Healthcare's NANO H5 and NANO H110, introduced in June 2021, highlights the industry's focus on efficiency and accuracy. These devices provide HbA1c results within 130 seconds, catering to the needs of medium to large laboratories.
From my personal experience working in a clinical setting, the shift towards point-of-care testing has markedly improved patient outcomes. The ability to obtain immediate HbA1c results allows for timely interventions, fostering better glycemic control. Patients appreciate the convenience and immediacy, which enhances their engagement and adherence to treatment plans.
Despite these advancements, challenges persist. The regulatory framework for product approvals can be lengthy and complex, posing significant hurdles for manufacturers. Additionally, ensuring patient adherence and awareness adds to the complexity of effective diabetes management. However, the ongoing focus on research and development, coupled with strategic industry collaborations, is expected to address these challenges, further propelling the growth of the Hemoglobin A1c Testing Devices for Diabetes Market in the United States.
Get an In-Depth Research Analysis of the US Hemoglobin A1c Testing Devices for Diabetes Market Size And Forecast [2025-2032]
Abbott
ARKRAY
Bio-Rad
PTS Diagnostics
Beckman Coulter
EKF Diagnostics
Roche
Menarini Group
Sebia
Siemens Healthcare
Tosoh
Trinity Biotech
Danaher Corporation
A. Menarini Diagnostics
HUMAN Diagnostics
OSANG Healthcare
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US Hemoglobin A1c Testing Devices for Diabetes Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US Hemoglobin A1c Testing Devices for Diabetes Market
Point-of-Care Testing Devices
Laboratory Testing Devices
Self-Monitoring Devices
Continuous Glucose Monitoring Systems
Wearable Devices
Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Diabetes Care Centers
Pharmacies
Chemical Methodology
Electrochemical Methodology
Optical Methodology
Microbial Methodology
Mass Spectrometry
Type 1 Diabetes Patients
Type 2 Diabetes Patients
Gestational Diabetes Patients
Prediabetic Patients
Other Diabetes-related Conditions
Direct Sales
Online Sales
Distributors and Wholesalers
Retail Pharmacies
Hospital Pharmacies
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Hemoglobin A1c Testing Devices for Diabetes Market Research Analysis
1. Introduction of the US Hemoglobin A1c Testing Devices for Diabetes Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US Hemoglobin A1c Testing Devices for Diabetes Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US Hemoglobin A1c Testing Devices for Diabetes Market, By Type
6. US Hemoglobin A1c Testing Devices for Diabetes Market, By Application
7. US Hemoglobin A1c Testing Devices for Diabetes Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US Hemoglobin A1c Testing Devices for Diabetes Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/